1201657-32-0Relevant articles and documents
Carbon-14 radiolabelling and tissue distribution evaluation of a potential anti-TB compound
Sonopo, Molahlehi S.,Venter, Kobus,Winks, Susan,Marjanovic-Painter, Biljana,Morgans, Garreth L.,Zeevaart, Jan R.
, p. 264 - 269 (2016)
This paper describes a five-step synthesis of a carbon-14-labelled pyrazole compound (11). A total of 2.96 MBq of 11 was obtained with the specific activity of 2242.4 MBq/mmol. The radiochemical purity was >99%, and the overall radiochemical yield was 60% based on the [14C6] 4-bromoaniline starting material. Biodistribution results showed that the radiotracer (administrated orally) has a high accumulation in the small intestine, large intestine and liver of both non-infected and tuberculosis (TB)-infected mice. Therefore, this suggests that compound 11 undergoes hepatobiliary clearance. The compound under investigation has been found to be slowly released from the liver between 2 and 8 h. The study revealed that 11 has no affinity for TB cells.
FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
-
Paragraph 00209, (2020/03/23)
The present invention relates to a fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or
DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF
-
Paragraph 0213; 0220, (2016/08/23)
The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.